Open access · OA
via OpenAlex
Drug repurposing of rapamycin mitigates amyloid beta associated proteotoxicity in Caenorhabditis elegans
Alkhudaydi, Samirah, author, Julie A. Moreno, Montrose, Luke, committee member, Arnold, Olivia, committee member, Hoernli, Frederic, committee member
· 2026
Loss of proteostasis
Deregulated nutrient-sensing
Chronic inflammation
Disabled macroautophagy
Rapamycin / mTOR inhibition
C. elegans
Abstract
Alzheimer's disease (AD) is the leading cause of dementia worldwide, affecting an estimated 55 million people and projected to exceed 130 million by 2050. Defined neuropathologically by the extracellular accumulation of amyloid-beta (Aβ) peptides and intracellular neurofibrillary tangles of hyperphosphorylated tau, AD currently lacks disease-modifying therapies capable of halting or reversing neurodegeneration. The proteotoxic accumulation of Aβ is a central pathogenic event, and strategies that enhance endogenous clearance mechanisms represent a compelling therapeutic area. mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) (sirolimus), a macrolide allosteric inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), is one of the most robustly validated pharmacological extenders of lifespan across model organisms and has demonstrated neuroprotective potential in mammalian AD models. Its capacity to provide mTORC1-mediated suppression of autophagy(definition) and to reduce neuroinflammation positions it as an attractive drug-repurposing candidate for AD. However, the extent to which rapamycin can mitigate Aβ proteotoxicity in Caenorhabditis elegans remains unexplored, and leveraging this model organism offers a powerful opportunity to study the mechanism by which rapamycin-mediated mTOR inhibition interacts with amyloid-β aggregation, clearance pathways, and proteostasis(definition) in the context of Alzheimer's-related neurodegeneration. In this study, we used two well-established transgenic Caenorhabditis elegans models of Aβ proteotoxicity: the muscle-specific temperature-inducible strain CL4176 (Pmyo-3
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.25675/3.027380
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
author, A.S., Moreno, J.A., member, M.L.C., member, A.O.C., & member, H.F.C. (2026). Drug repurposing of rapamycin mitigates amyloid beta associated proteotoxicity in Caenorhabditis elegans. https://doi.org/10.25675/3.027380
Vancouver
author AS, Moreno JA, member MLC, member AOC, member HFC. Drug repurposing of rapamycin mitigates amyloid beta associated proteotoxicity in Caenorhabditis elegans. 2026. doi:10.25675/3.027380.
BibTeX
@article{alkhudaydi2026Drugre,
title = {Drug repurposing of rapamycin mitigates amyloid beta associated proteotoxicity in Caenorhabditis elegans},
author = {Alkhudaydi, Samirah, author and Julie A. Moreno and Montrose, Luke, committee member and Arnold, Olivia, committee member and Hoernli, Frederic, committee member},
year = {2026},
doi = {10.25675/3.027380},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Science Translational Medicine 2019
Preprint · OA
Rapamycin and Alzheimer’s disease: Time for a clinical trial?
Daehwa Pharmaceutical Co., Ltd. 2016
Open access · US-GOV
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2013
Open access · OA
A canine model of human aging and Alzheimer's disease
CNS Neuroscience & Therapeutics 2023
Open access · CC-BY
mTOR signaling and Alzheimer's disease: What we know and where we are?
Molecular Neurodegeneration 2012
Open access · CC-BY
Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease
US Department of Veterans Affairs 1999
Open access · US-GOV